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SIRT1 takes down tumors
Y
uan et al. have identi-
fi  ed another anti-cancer 
effect of the “longevity” 
protein SIRT1. By speeding the 
destruction of the tumor promoter 
c-Myc, SIRT1 curbs cell division.
The yeast and nema-
tode equivalents of SIRT1 are 
fountains of youth that stretch 
lifespan. Whether SIRT1 slows aging in mammals isn’t certain, 
but it’s benefi  cial in other ways. The protein tunes up metabolism, 
reducing blood levels of glucose and insulin, and might forestall 
neurodegenerative illnesses such as Alzheimer’s disease and 
ALS. Given its pro-life credentials, you might expect SIRT1 
to inhibit cancer. And several studies suggest that it does. But 
other work indicates that the protein aids tumors. For example, 
SIRT1 chops off acetyl groups, which can inactivate the tumor 
suppressor p53.
Yuan et al. determined SIRT1’s effect on the transcription 
factor c-Myc, whose expression surges in many breast, colon, and 
liver cancers. The two proteins are tangled in a regulatory loop, the 
team found. c-Myc latched onto SIRT1’s promoter, spurring cells 
to manufacture more SIRT1. In turn, SIRT1 detached acetyl groups 
from c-Myc, hastening its breakdown. To test SIRT1’s effects on 
tumor growth, the researchers implanted cancerous cells expressing 
c-Myc into nude mice that lack immune defenses. Boosting 
production of SIRT1 blocked tumor formation.
How deacetylation of c-Myc sparks its destruction is still a 
mystery. The researchers say that the results don’t necessarily confl  ict 
with studies suggesting that SIRT1 is pro-tumor. Whether SIRT1 
promotes or prevents cancer probably depends on the situation.
Yuan, J., et al. 2009. J. Cell Biol. doi:10.1083/jcb.200809167.
Autophagosomes meet before they eat
H
ungry cells sometimes 
digest a portion of their 
contents inside struc-
tures called autophagosomes. 
Razi et al. identify a key step in 
autophagosome maturation, 
showing that it depends on early 
stages in the endocytic pathway 
that enables cells to absorb neces-
sities from their surroundings.
An autophagosome is like 
a miniature stomach that uses 
enzymes to dissolve macromol-
ecules and organelles. The pro-
cess of self-eating, known as autophagy, recaptures macromolecules 
and clears away potentially toxic protein tangles. But before an 
autophagosome can start digesting, it has to combine with endosomes 
and lysosomes that provide the necessary enzymes. Researchers knew 
that maturing autophagosomes fuse with late endosomes, which are far 
along in the endocytic pathway and break down absorbed material. But 
they didn’t know whether the youthful autophagosomes also merge 
with early endosomes that harbor freshly imbibed molecules.
To fi nd out, Razi et al. deleted components of the coatomer 
complex COPI, which is necessary for endosome function. Loss 
of COPI disrupted early endosomes, reducing absorption and 
processing of two molecules taken in via the endocytic pathway. 
COPI’s absence also gave cells indigestion: immature, nonfunctional 
autophagosomes built up in the cells.
The results suggest that to start working, an autophagosome has 
to fuse not just with late endosomes, but also with early endosomes. 
What the autophagosome gains from the rendezvous is a question for 
future studies. But the researchers suspect that early endosomes provide 
the molecular pump that helps acidify the autophagosome’s interior.
Razi, M., et al. 2009. J. Cell Biol. doi:10.1083/jcb.200810098.
A control cell (top) contrasts with a 
cell without COPI (bottom), where 
immature autophagosomes have 
accumulated.
When cancer cells can’t let go
L
ike a climber scaling a 
rock face, a migrating 
cancer cell has to keep a 
tight grip on the surface but also 
let go at the right moment to move 
ahead. Chan et al. reveal that the 
focal adhesion kinase (FAK) 
coordinates these processes to 
permit forward movement.
Crawling cancer cells send 
out extensions called invadopodia. By releasing enzymes that dissolve 
the extracellular matrix (ECM), invadopodia clear a path for the cell 
to wriggle through. As they move, cancer cells get traction by tempo-
rarily attaching to the ECM through focal adhesions. FAK spurs focal 
adhesions to disengage, and it is more abundant in metastatic tumors. 
Whether FAK also regulates invadopodia was unknown.
When Chan et al. removed FAK, breast cancer cells were 
much less invasive. But to the team’s surprise, the FAK-lacking 
cells sprouted extra invadopodia. The cells also sported large focal 
adhesions that were particularly sticky. The protein Src serves as 
FAK’s helper. FAK and Src work together to phosphorylate tyrosines 
in proteins such as paxillin, which then disassemble the focal adhesion. 
But the team found that in cells missing FAK, the phosphorylated 
proteins accumulated in the invadopodia. Src’s localization refl  ects 
this difference. In control cells, Src accumulated in focal adhesions. 
In FAK’s absence, Src headed to the invadopodia.
The work suggests that FAK controls movement by balancing 
the number of invadopodia that create a path for migration and 
the number of focal adhesions that hold the cell back. The next 
question, the researchers say, is how FAK and Src integrate these 
events to promote invasion.
Chan, K.T., et al. 2009. J. Cell Biol. doi:10.1083/jcb.200809110.
Cells that make c-Myc proliferate in 
culture (left), but not when SIRT1 is 
present (right).
The invadopodia (glowing dots) 
speckling a cell lacking FAK (left) 
are rare on a control cell (right).